A new gene-activation tool called TIGRa may overcome a major hurdle in treating eye diseases like glaucoma: it is small enough to be delivered directly into the body, where it activates protective genes in damaged retinal cells. In a mouse study, the treatment preserved partial vision after retinal injury, while untreated mice became nearly blind. The finding, published in August 2026 in Cell Stem Cell, suggests a promising path forward for therapies that current gene-editing tools like CRISPR cannot easily deliver.

Why Is Size Such a Big Problem for Gene Therapies?

Gene-editing tools like CRISPR work by finding target genes and turning up their expression, but they come with a significant practical problem: they are too bulky to fit inside the viral delivery vehicles that carry genetic instructions into cells. When researchers try to pack CRISPR instructions into a virus, the DNA manual is so lengthy that there is barely room for anything else. For therapies that need to adjust multiple genes at once, delivering separate CRISPR components becomes complicated and inefficient.

TIGRa solves this problem through sheer compactness. Its short DNA instructions fit comfortably inside viral vectors with room to spare, making it possible to target multiple genes in a single treatment. Once inside a cell, TIGRa works similarly to CRISPR-based tools by recruiting the cell's own machinery to ramp up expression of target genes. But TIGRa is more versatile in which genes it can target and more efficient at activating multiple genes simultaneously.

How Did Researchers Test TIGRa in the Eye?

The Stanford Medicine team chose the eye as their testing ground for good reason: vision is easy to measure, and results are immediately apparent. In their mouse model, researchers used TIGRa to activate two protective genes in retinal ganglion cells, the nerve cells that are damaged in glaucoma and other retinal degenerative conditions. When the retinal ganglion cells were injured, mice that received the TIGRa treatment retained partial vision. By contrast, mice that did not receive treatment became nearly blind.

"This is a tool that can be used to activate genes that otherwise lie dormant in our bodies," said Yang Sun, MD, professor of ophthalmology and senior author of the study.

Yang Sun, MD, Professor of Ophthalmology at Stanford University School of Medicine

Dr. Sun noted that the visual system offers a clear advantage for testing gene activation therapies. "It's easier to measure whether the eye is able to see than whether the liver is working," he explained. "In the visual system, you can tell right away".

Dr. Sun

Steps to Understanding How TIGRa Works in Retinal Protection

• Gene Activation: TIGRa finds target genes inside cells and recruits the cell's natural transcriptional machinery to increase their expression, turning up protective genes that would otherwise remain dormant.
• Neuroprotection: By activating multiple protective genes simultaneously in retinal ganglion cells, TIGRa helps preserve these nerve cells when they are damaged by injury or disease, maintaining vision function.
• Efficient Delivery: Unlike bulky CRISPR systems, TIGRa's compact DNA instructions fit inside viral vectors with room to spare, allowing researchers to deliver the therapy directly into the body without complex multi-component delivery schemes.

The implications extend beyond glaucoma. Retinal ganglion cells are damaged in multiple eye conditions, including various forms of retinal degeneration. The ability to activate neuroprotective genes inside the body opens new therapeutic possibilities for diseases where current treatments are limited or unavailable.

While the current work is in mice, the research represents a significant step toward gene therapies that can work inside the human body. The eye's accessibility and the clarity of vision outcomes make it an ideal organ for developing and refining gene activation approaches. As researchers continue to study TIGRa, the tool may eventually offer hope to patients facing vision loss from glaucoma and other retinal diseases where prevention of cell damage could preserve sight.